A new cohort of iPSC lines available from EBiSC will accelerate research into Huntington’s disease
“These iPSC lines offer great promise as a model system for HD research and therapeutic development, a terrible disease that devastates families across multiple generations,” explains Dan Felsenfeld, Director of Stem Cell Biology & Regenerative Medicine at CHDI. “A major focus of CHDI’s mission is to make resources such as these widely available to researchers to stimulate new research, as well as to support ongoing work of established investigators.” The donor samples were collected by researchers at University College London and Ulm University Medical Center in collaboration with CHDI. Donors included male and female volunteers aged 30 to 59 years; samples from HDGECs carry CAG expansions ranging from 41 through 50 repeats. Specific CAG-repeat data associated with individual iPSC lines is available via the EBiSC catalogue. Researchers interested in obtaining these lines should visit cells.ebisc.org/ and search ‘CHDI’. The EBiSC catalogue is in constant expansion and will continue collecting iPSC lines associated with neurodegenerative disorders like Huntington’s, Alzheimer’s, Parkinson’s and ALS as well as cardiovascular and eye disease, diabetes, muscular dystrophy and neuropathic pain. EBiSC has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI2 JU) in the context of the projects EBiSC (Grant Agreement No 115582) and EBiSC2 (Grant Agreement No 821362). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Keywords
iPSC, Research, Huntington's disease, EBiSC catalogue, CHDI Foundation, Therapy